Meropenem Venus Pharma

Meropenem, the active ingredient in Meropenem Venus Pharma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, nosocomial pneumonia, meningitis, severe urinary tract infections, and sepsis in hospitalized patients, and is indicated for both adult and pediatric use when alternative agents are unsuitable.

GNH USA supplies Meropenem Venus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used for severe bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: provides rapid bactericidal activity to resolve infection and prevent progression. Nosocomial pneumonia: eradicates resistant pathogens causing hospital‑acquired lung infections. Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis effectively. Severe urinary tract infections: eliminates causative organisms in complicated UTIs. Sepsis and septic shock: offers critical coverage against multi‑drug‑resistant bacteria in systemic infections.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or pruritus. - Infusion site reactions: pain, erythema, or phlebitis at the injection site. - Headache: transient and usually resolves. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders or renal impairment. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: acute hypersensitivity reaction with respiratory or circulatory compromise. - Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal toxicity: acute kidney injury in susceptible individuals. - Neutropenia or agranulocytosis: marked reduction in white blood cell counts.

Meropenem should be used with caution in specific clinical situations.

Renal function: adjust dosing in patients with impaired renal clearance. Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactam antibiotics. Seizure risk: monitor closely in patients with a history of seizures or central nervous system disorders. Pregnancy: prescribe only when the potential benefit justifies the potential risk to the fetus. Drug interactions: review concomitant medications for possible interactions that may affect efficacy or safety. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several drugs; clinical assessment is required.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk. - Warfarin: may potentiate anticoagulant effect, necessitating INR monitoring. - Probenecid: can increase meropenem plasma concentrations, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic risk when combined with other nephrotoxic agents. - Other β‑lactam antibiotics: potential for additive toxicity; assess necessity of combination therapy.